Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

GHK-Cu vs BPC-157 for Anti-Ageing Research UK 2026

GHK-Cu vs BPC-157 for Anti-Ageing Research UK 2026 Research Use Only. Not for human therapeutic use. All data cited from peer-reviewed preclinical literature. GHK-Cu (copper tripeptide Gly-His-Lys) and BPC-157 (Body Protection Compound-157) are two of the most

By Recovery & Performance Peptides Editorial Team

GHK-Cu vs BPC-157 for Anti-Ageing Research UK 2026

Research Use Only. Not for human therapeutic use. All data cited from peer-reviewed preclinical literature.

GHK-Cu (copper tripeptide Gly-His-Lys) and BPC-157 (Body Protection Compound-157) are two of the most studied research peptides in the context of tissue repair and biological age-related decline. Both compounds have documented effects on wound healing, collagen biology, angiogenesis, and anti-inflammatory mechanisms — yet through substantially different receptor systems, signalling cascades, and primary tissue targets. Understanding the mechanistic differences, complementary strengths, and overlapping biology between GHK-Cu and BPC-157 is valuable for researchers designing studies in ageing biology, regenerative medicine, and multi-compound research protocols. This comparative post examines the research biology of each compound across key anti-ageing domains.

🔗 Also See: For complete individual profiles, see our GHK-Cu UK Complete Research Guide 2026 and BPC-157 UK Complete Research Guide 2026.

Mechanism Overview: How Each Compound Acts

GHK-Cu is a naturally occurring tripeptide-copper complex formed endogenously from the cleavage of the α2-macroglobulin C-terminus. Its plasma levels decline from ~200 ng/mL in young adults to ~80 ng/mL in older individuals — a 60% reduction that correlates with declining tissue repair capacity. GHK-Cu acts primarily through gene expression reprogramming: whole-genome microarray and RNA sequencing studies demonstrate that GHK-Cu modulates ~4,000 genes in human fibroblasts and lung fibroblasts. Key transcriptomic effects include upregulation of collagen synthesis genes (COL1A1, COL3A1), decorin, antioxidant genes (SOD1, CAT, GPX1), BDNF, neurotrophin receptors, and proteasome/ubiquitin pathway components. Copper delivery to cuproenzymes (SOD1, cytochrome c oxidase, lysyl oxidase) is a direct biochemical activity contributing to antioxidant and collagen cross-linking effects. GHK-Cu also suppresses TGF-β1/SMAD-mediated fibrosis and activates Nrf2-ARE antioxidant response elements.

BPC-157 is a synthetic pentadecapeptide stabilised against acid hydrolysis, acting through multiple receptor systems including VEGFR2, FAK (focal adhesion kinase), EGR1 (early growth response protein 1), and eNOS to produce angiogenesis, tissue repair, anti-inflammatory, and neuroprotective effects. BPC-157 does not have a single defined receptor — rather, it modulates multiple convergent pathways: VEGF-VEGFR2-eNOS (angiogenesis and NO production), FAK-paxillin-actin (cytoskeletal remodelling and cell migration), NF-κB suppression (anti-inflammatory), PI3K-Akt-Bcl-2 (anti-apoptotic), and EGR1-driven collagen/fibronectin gene transcription. Unlike GHK-Cu, BPC-157 is stable across all pH ranges and is active both orally and parenterally in preclinical models.

Collagen and Extracellular Matrix Biology

GHK-Cu is one of the most extensively studied collagen-modulating peptides in dermatological research. It directly upregulates COL1A1, COL1A2, and COL3A1 at the mRNA level in human skin fibroblasts (quantified by qRT-PCR and northern blot), increases collagen protein synthesis (measured by [³H]-proline incorporation into hydroxyproline-containing collagen peptides by Sircol assay), and promotes lysyl oxidase activity (copper-dependent — cross-linking collagen fibrils for tensile strength). In aged skin models (fibroblasts from donors >60 years old), GHK-Cu restores collagen synthesis to near-young adult levels. Decorin upregulation by GHK-Cu is mechanistically significant: decorin is a small leucine-rich proteoglycan that organises collagen fibrils, sequesters TGF-β1 (reducing fibrosis), and suppresses tumour cell growth. GHK-Cu also downregulates MMP-1, -2, and -9 (collagen-degrading metalloproteinases) while upregulating TIMP-1 and TIMP-2 — shifting ECM balance toward synthesis.

BPC-157 promotes collagen synthesis through EGR1 transcription factor activation: EGR1 binds GC-rich promoter elements in collagen (COL1A1, COL3A1), fibronectin, and VEGF genes, driving coordinate upregulation of repair-phase ECM components. In tendon research — BPC-157’s most extensively studied collagen context — tendon fibroblast proliferation, type I collagen secretion (Sircol assay), and tendon breaking force/load-to-failure (biomechanical testing of Achilles/patellar/MCL tendons in surgically transected rat models) are significantly improved by BPC-157. This tendon-collagen focus distinguishes BPC-157 from GHK-Cu: BPC-157 works preferentially in load-bearing connective tissue (tendon, ligament, muscle-tendon junction), while GHK-Cu’s collagen effects are best characterised in dermal fibroblasts and skin architecture.

Angiogenesis Research

GHK-Cu promotes angiogenesis through VEGF upregulation and copper-mediated metalloproteinase activities that remodel the basement membrane to allow endothelial sprouting. In the CAM (chorioallantoic membrane) assay and Matrigel plug assay, GHK-Cu increases vessel density. Mechanistically, copper delivery to HIF-1α (hypoxia-inducible factor) stabilisation may contribute — copper is required for HIF-1α prolyl hydroxylase activity regulation. However, GHK-Cu angiogenesis is generally considered a secondary activity to its transcriptomic collagen/antioxidant effects.

BPC-157 is among the most potent research peptide angiogenesis stimulators. The aortic ring assay (ex vivo sprouting from rat aortic rings embedded in Matrigel), Matrigel plug assay (in vivo CD31-stained vessel density), and HUVEC tube formation assay (Angiogenesis Analyser quantification) all demonstrate robust, reproducible BPC-157-driven angiogenesis. The mechanism — VEGF-A upregulation (ELISA, RT-qPCR), VEGFR2 phosphorylation (pY1175 western blot), and eNOS Akt-Ser1177 phosphorylation (NO bioavailability for vasodilation and tube formation) — is well-characterised. BPC-157’s pro-angiogenic activity is arguably its most consistent effect across tissue types, explaining its broad repair efficacy in gastric mucosa, tendon, muscle, bone, liver, heart, and kidney.

Verdict for angiogenesis research: BPC-157 is the stronger angiogenesis research tool with more consistently documented and mechanistically defined angiogenic activity. GHK-Cu provides angiogenesis support primarily through VEGF upregulation but lacks BPC-157’s VEGFR2-eNOS mechanistic precision in the published literature.

Antioxidant and Senescent Cell Biology

GHK-Cu has particularly strong antioxidant research evidence. Transcriptomic studies show GHK-Cu upregulates SOD1, SOD2, CAT, GPX1, PRDX1, and TXNRD1 — a comprehensive antioxidant gene signature. Copper metalloprotein delivery (SOD1 is a Cu-Zn enzyme) directly enhances enzymatic ROS dismutation. In lung fibroblast cultures, GHK-Cu reverses the gene expression signature of aged/oxidatively stressed cells toward a younger phenotype — a remarkable transcriptomic “rejuvenation” effect documented by Pickart and colleagues. Senescent cell SASP (senescence-associated secretory phenotype) suppression is an emerging GHK-Cu research area: GHK-Cu reduces SA-β-galactosidase activity (senescence marker), p16/p21 expression, and SASP cytokine secretion (IL-6, IL-8, GDF15) in hydrogen peroxide-induced premature senescence models — mechanistically through NF-κB suppression and p53 pathway modulation.

BPC-157 engages antioxidant pathways through Nrf2-HO-1-NQO1 activation (documented in ischaemia, SCI, and hepatotoxicity models), reducing oxidative stress markers (4-HNE, 8-OHdG, protein carbonyl) in multiple tissue contexts. However, BPC-157 lacks the comprehensive antioxidant gene transcriptomic signature that GHK-Cu demonstrates — its antioxidant effects are more contextually secondary to angiogenesis and anti-inflammation.

Verdict for antioxidant/senescence research: GHK-Cu is the stronger candidate for antioxidant and cellular senescence research, given its documented broad antioxidant transcriptome remodelling and direct SASP modulation. BPC-157 provides Nrf2-dependent antioxidant support but is less specifically a transcriptomic antioxidant tool.

Neurological and Neuroprotection Biology

GHK-Cu has been increasingly investigated for neurological activity. Transcriptomic studies show GHK-Cu upregulates BDNF, NGF, GDNF, and their receptors (TrkA, TrkB, p75NTR) in neural tissue models — a neurotrophic gene signature relevant to neurodegeneration research. In Alzheimer’s disease research, GHK-Cu has been studied for its capacity to reduce Aβ₁₋₄₂ aggregation (measured by ThioT fluorescence and atomic force microscopy) through copper chelation from amyloid-promoting Cu-Aβ complexes, and to reduce tau hyperphosphorylation markers. Spinal cord contusion models show BBB locomotor score improvement with GHK-Cu treatment. GHK-Cu’s gene expression database analyses (LINCS L1000) show transcriptomic similarity to known neuroprotective compounds — suggesting broad CNS-relevant pathway modulation.

BPC-157 has a well-characterised neuroprotective profile across ischaemia (MCAO infarct reduction), TBI (CCI contusion volume reduction), SCI (BBB locomotor score improvement), Parkinson’s (MPTP/6-OHDA dopaminergic protection), and excitotoxicity models. Its mechanisms — PI3K-Akt survival signalling, NF-κB neuroinflammation suppression, VEGF angiogenesis in the injured CNS — are multi-targeted and reproducibly demonstrated. BPC-157 also modulates dopaminergic and GABAergic neurotransmitter pathways, including reversal of neuroleptic-induced catalepsy and interactions with the gut-brain axis through ENS biology.

Verdict for neuroprotection research: BPC-157 has a stronger and more extensively validated neuroprotection profile across standardised injury models with defined endpoints. GHK-Cu offers a complementary neurotrophic gene-expression angle (BDNF/NGF upregulation, Aβ-copper interaction biology) that is mechanistically distinct and particularly relevant to neurodegeneration research.

Wound Healing and Skin Research

GHK-Cu is the gold-standard peptide for skin wound healing and dermatological research — with the most extensive published literature in this domain. Topical application of GHK-Cu accelerates wound closure (full-thickness excisional wounds in rodents, wound area tracing, digital planimetry), increases granulation tissue thickness (H&E histology), promotes re-epithelialisation (K14/K5 basal keratinocyte IHC, Ki-67 proliferation), and reduces scar width and fibrosis (Masson’s trichrome, collagen bundle organisation by SHG microscopy). GHK-Cu also promotes dermal fibroblast proliferation (MTT, CFSE dilution) and migration (scratch assay, Boyden chamber) at concentrations of 1–10 μM. In aged skin, GHK-Cu restores the structural and functional characteristics of younger tissue through transcriptome remodelling.

BPC-157 promotes wound healing with documented efficacy in gastric ulcer, intestinal anastomosis, muscle injury, tendon, and skin models. In excisional skin wound models, BPC-157 (1–10 μg/kg i.p. or topical) significantly accelerates closure and granulation tissue formation — but the skin-specific literature is less extensive than for tendon, muscle, and GI repair. BPC-157’s angiogenic activity is particularly relevant to chronic non-healing wound contexts where vascular insufficiency is the limiting factor.

Verdict for skin/wound healing research: GHK-Cu is the primary candidate for skin-specific wound healing and dermatological anti-ageing research. BPC-157 provides important angiogenic support relevant to chronic wound and multi-tissue repair contexts.

Inflammatory Biology and Immune Modulation

GHK-Cu broadly suppresses pro-inflammatory gene expression: transcriptomic analyses show GHK-Cu downregulates NFκB pathway genes, IL-6, TNF-α, IL-1β, MCP-1, and upregulates anti-inflammatory mediators including IL-10 and TGF-β3. In LPS-stimulated macrophage cultures (RAW 264.7), GHK-Cu reduces NO production (Griess assay), iNOS expression, and TNF-α/IL-6 secretion. Its broad gene-regulatory effect on immunity is consistent with its role as an endogenous tissue damage signal that simultaneously promotes repair while dampening excessive inflammation.

BPC-157 is a potent NF-κB inhibitor across multiple tissue contexts — reducing NF-κB p65 nuclear translocation, IκBα phosphorylation, and downstream iNOS, COX-2, TNF-α, and IL-1β production. BPC-157’s anti-inflammatory activity is documented in GI (IBD, NSAID-injury), systemic (endotoxaemia, sepsis models), musculoskeletal (tendon, muscle), and CNS (neuroinflammation) contexts. Unlike GHK-Cu, BPC-157 also modulates the dopaminergic and serotonergic neuroinflammation axes — relevant to systemic inflammatory conditions with neuroimmune involvement.

Combination Research: Complementary Mechanisms

GHK-Cu and BPC-157 operate through largely non-overlapping primary mechanisms, making them scientifically logical combination candidates in multi-compound research designs. GHK-Cu’s copper metalloprotein delivery and broad antioxidant transcriptome remodelling complement BPC-157’s VEGFR2-driven angiogenesis and FAK-paxillin cytoskeletal repair activity. GHK-Cu’s collagen gene transcription approach (COL1A1/COL3A1 direct upregulation) complements BPC-157’s EGR1-driven fibronectin-collagen induction in a different ECM geometry context (dermal vs tendon/muscle).

Research designs examining combination effects use factorial treatment matrices (vehicle, GHK-Cu alone, BPC-157 alone, GHK-Cu+BPC-157) to assess additive, synergistic (Bliss independence or Loewe additivity modelling), or antagonistic interactions. Dose-response surface analysis (ComboSyn software, Chou-Talalay method) formally quantifies combination index (CI) — CI <1 indicating synergy, CI = 1 additivity, CI >1 antagonism — across biologically relevant endpoints (wound closure rate, collagen synthesis, tube formation). Given their mechanistic complementarity, synergy in wound repair outcomes is a testable and scientifically plausible hypothesis, though this remains to be formally evaluated in published preclinical research as of 2026.

Summary Comparison Table

Primary mechanism

Gene expression remodelling, Cu metalloprotein delivery, Nrf2 activation

VEGFR2-eNOS angiogenesis, FAK-paxillin cytoskeletal repair, NF-κB suppression

Collagen biology

Strong — COL1A1/COL3A1 upregulation, lysyl oxidase, decorin; dermal focus

Moderate — EGR1-driven; tendon/connective tissue focus

Angiogenesis

Moderate — VEGF upregulation, Cu-HIF

Strong — VEGFR2-eNOS, documented in multiple models

Antioxidant

Strong — SOD1/CAT/GPX1 transcriptomic signature, Cu delivery

Moderate — Nrf2-HO-1 contextual activation

Senescence (SASP)

Strong — SASP suppression, SA-β-gal reduction

Not characterised in senescence models

Skin/wound healing

Primary strength — extensive dermatological literature

Documented, less skin-specific than GHK-Cu

Neuroprotection

Emerging — BDNF/NGF upregulation, Aβ-Cu interaction

Strong — validated across ischaemia, TBI, SCI, PD models

GI biology

Limited data

Primary strength — ulcer, IBD, motility, gut-brain axis

Oral bioavailability

Limited (Cu complex oral stability uncertain)

Active orally and parenterally in rodent models

Best for research

Skin ageing, antioxidant biology, SASP, collagen transcriptomics

Angiogenesis, multi-tissue repair, GI, CNS, systemic protection

All comparisons are based on preclinical research data. Both compounds are Research Use Only with no human therapeutic claims implied.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified GHK-Cu and BPC-157 for research and laboratory use. View UK stock →

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Myths: Higher Isn't Faster, and More Isn't Better

The most common BPC-157 dosing error is the assumption that doubling the dose doubles the healing rate. Animal studies used doses ranging from 10mcg/kg to 10mg/kg body weight depending on injury model. A 1000-fold range that marketers cherry-pick to justify protocols between 250mcg and 2mg daily in humans. What those protocols ignore: dose-response curves plateau. The study published in the Journal of Physiology Paris that demonstrated Achilles tendon healing in rats used 10mcg/kg. That's roughly 700mcg for a 70kg human. Doses above that threshold showed no additional benefit in healing time or tensile strength recovery. The BPC-157 receptor mechanism isn't fully characterized, but evidence points to VEGF (vascular endothelial growth factor) upregulation and nitric oxide pathway modulation as primary actions. Both pathways saturate at specific tissue concentrations. Adding more peptide doesn't recruit more VEGF receptors or increase NO synthase activity beyond the biological ceiling. Exceeding therapeutic dose creates waste, not results. We've reviewed user logs from peptide forums where individuals escalated from 500mcg to 1.5mg daily after 'hitting a plateau,' then reported no change in recovery trajectory over the following four weeks. That's $180–$240 spent on excess peptide that provided zero incremental benefit. Start at 250–500mcg per day split into two subcutaneous injections. Run that dose for 4–6 weeks and assess. If results stall, the bottleneck is almost never in…
STORAGE

Reconstitution, Storage & Prep

BPC-157 typically comes as a lyophilized (freeze-dried) powder that requires reconstitution before use. Reconstitution Process: Allow the BPC-157 vial to reach room temperature Use bacteriostatic water (BAC water) as the reconstitution fluid (this contains 0.9% benzyl alcohol as a preservative) Draw the appropriate amount of BAC water into an insulin syringe Inject the water slowly down the inside wall of the vial, allowing it to gently dissolve the powder Do not shake vigorously, but gentle swirling is acceptable Allow the solution to sit until fully dissolved (typically a few minutes) Common Reconstitution Ratio: 5 mg BPC-157 + 5 mL BAC water = 1 mg/mL (100 mcg per 0.1 mL / 10 units on an insulin syringe) Storage Guidelines: Lyophilized (unreconstituted) BPC-157: Store below -18°C (-0.4°F) for long-term storage; stable at room temperature for approximately 3 weeks Reconstituted BPC-157: Store at 2 to 8°C (refrigerator temperature) and use within 4 weeks Protect from light and avoid repeated freeze-thaw cycles Never use the solution if it appears cloudy or contains particles
02

Question drills

Open a question for its connected answer.

01What If Different Cell Lines Show Contradictory Responses to BPC-157?+

Cell line variability is real. Primary cells from human donors respond differently than immortalized cell lines, and responses vary between species (rat vs human). When contradictions appear, researchers prioritize primary human cells over immortalized lines and look for dose-dependent patterns across multiple cell sources. If BPC-157 promotes migration in primary human fibroblasts but not in an immortalized mouse line, the human primary data carries more weight for translational potential.

SOURCE / realpeptides.co ↗
02What If the Peptide Loses Activity During Storage or Handling?+

Store lyophilized BPC-157 at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. BPC-157 animal research protocols typically prepare fresh solutions every 7–14 days, and studies document activity loss when peptides are exposed to repeated freeze-thaw cycles or stored at room temperature beyond 24 hours. Temperature excursions above 25°C for extended periods likely denature the peptide structure, rendering it inactive—visual inspection cannot detect this.

SOURCE / realpeptides.co ↗
03What If Someone With MS Wants to Try BPC-157 Based on Animal Data?+

Consult a neurologist before using any research peptide alongside disease-modifying therapies. BPC-157 studied MS research exists only in animal models. There's no published safety data for concurrent use with interferon-beta, glatiramer acetate, natalizumab, or other MS medications. The peptide's immunomodulatory effects could theoretically interact with DMTs that suppress or redirect immune function. If a physician agrees to monitor off-label use, baseline inflammatory markers (CRP, ESR), liver function tests, and renal function should be checked before starting, with follow-up testing at 4–6 week intervals.

SOURCE / realpeptides.co ↗
04What If Baseline Gene Expression Is Already Elevated in Chronic Injury?+

BPC-157's effects are most pronounced in acute injury models where baseline expression is low. In chronic injury states with pre-existing inflammation, the peptide's ability to further upregulate repair genes may be attenuated. Some studies show only 1.5–2-fold increases rather than 3–4-fold. This suggests BPC-157 is most effective when administered early in the injury timeline, ideally within the first 72 hours when inflammatory signaling is transitioning to proliferative repair.

SOURCE / realpeptides.co ↗
05What If I Want to Use BPC-157 After ACL Reconstruction Surgery?+

Contact your orthopedic surgeon before initiating any peptide protocol post-operatively. BPC-157 is not FDA-approved and has no established human safety data in post-surgical contexts. Your surgeon needs to document any non-standard interventions you pursue, particularly if complications arise that require revision surgery. Animal models suggest potential benefit in graft integration, but human application introduces variables (immune response to compounded peptides, infection risk from non-sterile vials, interaction with prescribed analgesics or antibiotics) that research models don't account for.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research perspective on BPC-157: potential therapeutic applications

BPC-157 is a “Pentadeca Peptide” which was derived from a naturally occurring peptide found in gastric secretions. In other words, a healthy stomach produces, in very small amounts, this unique peptide, which helps keep the lining of the stomach intact. Researchers figured out a way to make a stable version of this peptide, and BPC-157 was born. There are few peptides out there that have such a far-reaching effect on so many aspects of health. Most peptides are releasers of Growth Hormone, and have very little effect outside of the reach of benefits found from increased GH release. What makes BPC-157 so special to me, is that it positively affects every aspect of health. It can heal stomach ulcers, it can repair nerves, and soft tissue (aka ligaments and tendons). It also has been shown to reduce depressive behaviours as well as protect against addiction mechanisms (via its effect on GABA transmission as well as Dopamine and serotononin transmission, etc.) Here’s a quick break-down of the top 5 benefits of BPC-157. Say Good-bye to Ulcers BPC-157 was originally developed because it was found in gastric acid, and promotes healing of gastric ulcers, as well as intestinal health. What’s more, this is one of the few peptides that has an effect when taken orally. Something that other peptides can’t promise.“particularly, it has a prominent effect on alcohol-lesions (i.e. acute, chronic) and naiads lesions (interestingly, bpc 157 both prevents and reverses adjuvant arthritis). In rat esophagitis and failed function of both lower esophageal sphincter (les) and pyloric sphincters (ps), bpc 157 increased pressure in both sphincters till normal and reduced esophagitis.” Anti-Inflammatory Effects BPC-157 has far-reaching anti-inflammatory benefits, and has been studied for its effect on gingivitis and periodontitis (inflammation of the gums and oral-tissue). “The pentadecapeptide bpc 157 has been shown to have anti-inflammatory and wound healing effects on multiple target tissues and organs. The purpose of the present study was to investigate the effect of bpc 157 on inflammation and bone resorption in experimental periodontitis in rats. First the acute effect of bpc was tested on gingival blood flow by laser doppler flowmetry. Then periodontitis was produced by a silk ligature placed around the lower left first molar. Rats were treated with bpc 157 (once daily for 12 days) or vehicle. At day 13, the gingivomucosal tissues encircling the molars were removed on both sides. Inflammation was assessed by evans blue plasma extravasation technique and by histology. Alveolar bone loss was analyzed by microct. Bpc 157 had no effect on gingivomucosal blood flow. Twelve day ligature caused a significantly increased evans blue extravasation in the gingivomucosal tissue, histological signs of inflammation, and alveolar bone destruction. Bpc 157 treatment significantly reduced both plasma extravasation, histological alterations and alveolar bone resorption. In conclusion, systemic application of bpc 157 does not alter blood circulation in healthy gingiva. Chronic application of the peptide has potent antiinflammatory effects on periodontal tissues in ligature induced periodontitis in rats. Taken together, this proof of concept study suggests that bpc 157 may represent a new peptide candidate in the treatment of periodontal disease.” Soft-Tissue Healing One of the most important effects of BPC-157, even though I don’t focus on it as much, is that it positively impacts the healing of soft tissue. Ligament and tendon healing is very difficult to pull off. There is very little blood-flow to this tissue in the body. Most peptides that affect GH levels have very little effect on soft tissue, and this makes BPC-157 unique in its own right. “We improved medial collateral ligament (mcl) healing throughout 90 days after surgical transection. We introduced intraperitoneal, per-oral (in drinking water) and topical (thin cream layer) peptide therapy always given alone, without a carrier. Previously, as an effective peptide therapy, stable gastric pentadecapeptide bpc 157 (gepppgkpaddaglv, an anti-ulcer peptide effective in inflammatory bowel disease therapy (pl 14736)) particularly improved healing of transected tendon and muscle and wound healing effect including the expression of the early growth response 1 (egr-1) gene. After mcl transaction bpc 157 was effective in rats when given once daily intraperitoneally (10 microg or 10 ng/kg) or locally as a thin layer (1.0 microg dissolved in distilled water/g commercial neutral cream) at the site of injury, first application 30 min after surgery and the final application 24 h before sacrifice. Likewise, bpc 157 was effective given per-orally (0.16 microg/ml in the drinking water (12 ml/day/rat)) until sacrifice. Commonly, bpc 157 microg-ng-rats exhibited consistent functional, biomechanical, macroscopic and histological healing improvements. Thus, we suggest bpc 157 improved healing of acute ligament injuries in further ligament therapy.” Antidepressant Effects BPC-157 is one of the only peptides I’ve ever researched that has a dramatic effect on mood and wellbeing. Sure, the benefits of increased GH output from peptides like Ipamorelin can have an effect on mood and wellbeing. But when it comes to a specific effect on mood and mental health, BPC-157 stands alone. “Various antidepressants have antiulcer activity. Likewise, the models currently used in ulcers and depression disorders research have a considerable degree of similarity. Therefore, the possibility that depression disorders could be effectively influenced by a primary antiulcer agent with a cyto/organoprotective activity, such as the novel stomach pentadecapeptide bpc 157, was investigated in two rat depression assays. First, a forced swimming test (a porsolt’s procedure) was used. As a more severe procedure, chronic unpredictable stress (after 5 d of unpredictable stress protocol, once daily drug application during stress procedure, open field-immobility test assessment at fourth or sixth day of medication) was used. In a forced swimming test, a reduction of the immobility time in bpc 157 (10 microg, 10 ng x kg(-1) i.p.) treated rats corresponds to the activity of the 15 mg or 40 mg (i.p.) of conventional antidepressants, imipramine or nialamide, respectively, given according to the original porsolt’s protocol. In chronic unpredictable stress procedure, particular aggravation of experimental conditions markedly affected the conventional antidepressant activity, whereas bpc 157 effectiveness was continuously present. The effect of daily imipramine (30 mg) medication could be seen only after a more prolonged period, but not after a shorter period (i.e., 4-d protocol). In these conditions, no delay in the effectiveness was noted in bpc 157 medication and a reduction of the immobility of chronically stressed rats was noted after both 4 and 6 d of bpc 157 (10 microg, 10 ng) medication.” Addiction-Fighting Effects Last, but not least, BPC-157 has a strong effect on addiction-related neurotransmission. It enhances GABA transmission and reduces benzodiazepine tolerance. “A novel gastric pentadecapeptide bpc 157 with different beneficial activities and anticonvulsant effect interacting with gabaergic system could improve diazepam efficacy coadministered (10 microg/kg, 10 ng/kg i.p.) with diazepam (5.0 mg/kg i.p.) twice daily for 10 days, since diazepam chronic medication would otherwise predispose for diazepam- tolerance/withdrawal development (shorter latency to convulsion after convulsant). In diazepam chronically treated mice, it attenuated diazepam tolerance (provoked by later acute administration of diazepam together with convulsant) and postponed physical dependence/withdrawal effects (provoked by later administration of isoniazid). In tolerance assay, at 42 h after the end of conditioning regimen, shorter preconvulsive latencies than in healthy (non-diazepam conditioned) mice following isoniazid (800 mg/kg i.p.) (as hallmark of tolerance) were observed if diazepam (5.0 mg/kg i.p.) was again given acutely to mice previously conditioned with diazepam alone (use of picrotoxin 3.0 mg/kg i.p., as convulsant, with acute application of diazepam in previously diazepam conditioned mice did not lead to tolerance hallmark). This was completely avoided in diazepam+bpc 157 10 microg or diazepam+bpc 157 10 ng chronically treated animals. In physical dependence assay (isoniazid challenge assessed at 6, 14, 42 and 72 h after conditioning medication), when compared to diazepam non-conditioned healthy mice, in diazepam conditioned mice residual anticonvulsive activity was not present already at the earliest post-conditioning interval (i.e., not different latency to isoniazid-convulsions), whereas shorter preconvulsive latencies (as physical dependence/withdrawal hallmark) were noted in diazepam conditioned mice following isoniazid challenge at 42 h and at 72 h after end of conditioning treatment. In diazepam+bpc 157 10 microg- conditioned mice, a residual anticonvulsive activity (i.e., longer latency to isoniazid convulsion) was noted at 6 h post-conditioning, whereas shorter preconvulsive latencies appeared only at 72 h-post-conditioning period. In conclusion, taken together these data (lack of tolerance development (tolerance studies), prolonged residual anticonvulsive activity, and postponed physical dependence/withdrawal hallmark in diazepam+bpc 157 chronically treated mice) with common benzodiazepines tolerance/withdrawal knowledge, it could be speculated that bpc 157 acts favoring the natural homeostasis of the gaba receptor complex as well as enhancing the gabaergic transmission, and having a mechanism at least partly different from those involved in diazepam tolerance/withdrawal, it may be likely used in further therapy of diazepam tolerance and withdrawal.” And also reduces the hyperactivity that occurs when methamphetamine was administered to rats. “Stabile gastric pentadecapeptide bpc 157, gly–glu–pro–pro–pro–gly–lys–pro–ala–asp–asp–ala–gly–leu–val, mw 1419, has a variety of protective effects in different organs, as well as nervous system. It antagonizes haloperidol-induced behavioural supersensitivity to amphetamine which, results in dopaminergic neurotoxicity and nigrostriatum damage due to increased lipid peroxidation. Currently, bpc 157 neuroprotective effects are evaluted in a model of haloperidol- and methamphetamine-induced neurotoxicity. These models result in impaired motoric function and increased lipid peroxidation in different brain regions. The purpose of this research was to asses bpc 157 protective effects on nigrostriatum in rat model of haloperidol and methamphetamine induced neurotoxicity using fine motoric in rats as indicator of nigrostriatum function and malondialdehyde (mda) levels as lipid peroxidation marker.” WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D. S., Brcic, L., Sever, M., & Slobodnjak, Z. (2010). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 16(10), 1224–1232. PubMed Staresinic, M., Petek, M., Perovic, D., Coric, V., Zoricic, I., Zoricic, Z., & Sikiric, P. (2003). Healing of Achilles tendon in rats: advanced healing by BPC 157 and its possible mechanisms. Journal of Orthopaedic Research, 21(5), 976–983. PubMed Vukojevic, J., Sikiric, P., et al. (2018). Pentadecapeptide BPC 157 and the healing of transected quadriceps muscle in rats: new insights. European Journal of Pharmacology, 833, 160–170. PubMed Seiwerth, S., Brcic, L., Vuletic, L. B., Kolenc, D., & Sikiric, P. (2014). BPC 157 and blood vessels. Current Pharmaceutical Design, 20(7), 1121–1125. PubMed Mihovilovic, K., Sever, M., Zoricic, I., et al. (2007). Anti-inflammatory and anti-ulcer effects of stable gastric pentadecapeptide BPC 157 in rodent models of gastrointestinal lesions and periodontitis. Journal of Physiology and Pharmacology, 58(Suppl 5), 161–176. PubMed Sikiric, P., Hahm, K. B., Blagaic, A. B., & Tvrdeic, A. (2020). Stable gastric pentadecapeptide BPC 157, safe in clinical trials, may solve major health problems. World Journal of Gastroenterology, 26(24), 3090–3107. PubMed

RESEARCH

In Studies

Most of the studies on BPC-157 have been on animals, and the route of administration and doses that were given vary. It has been administered orally, intraperitoneally, subcutaneously, topically, and intravenously in doses that range from 10ng/kg to 50µg/kg. Animal studies have demonstrated that BPC-157 remains stable, even when exposed to gastric juices. It is able to exert its beneficial effects in tissues far beyond the GI system when administered orally, which would suggest that it is absorbed through the gut and transported throughout the body. In human studies, BPC-157 has been delivered orally and intravenously. The human pilot study on BPC-157 found that it was tolerated well in doses of up to 20mg when given intravenously, and no adverse side effects were seen [14]. A Phase I human trial has also been conducted, where participants were given up to 9mg of BPC-157 orally each day for 2 weeks. Unfortunately, the results of this study were never published [15]. If you were to compare the doses given to humans and animals purely based on milligrams given per kilogram of body weight, human studies have used relatively high doses of BPC-157. Of course, it is unwise to directly compare the doses given to animals and the doses given to humans, as the body’s surface area should also be taken into account when translating doses between species. But if this factor is taken into account, the doses humans were given in the pilot study still exceed those that have been tested in animals. At this point, it should be noted that only 2 humans participated in the pilot study, and only the tolerability of BPC-157 was scrutinised, not its potential health benefits.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 vs TB-500

BPC-157 vs TB-500 compared head-to-head: mechanisms, dosage, efficacy, side effects, and when to use each. Plus: the Wolverine Stack protocol.

Continue reading

Related articles